Regional features of the incidence of chronic Ph-negative myeloproliferative neoplasms in Belarus

According to published data, there are differences in the registered incidence of chronic Ph-negative myeloproliferative neoplasms (MPN) in some regions of the world. In this study, for the first time, we compare the Ph- MPN incidence in the regions of Belarus in order to determine the regional features.

It was shown that for the period 2014-2018 the highest rates of standardized incidence of polycythemia vera were noted in the Brest region – 1,17 and Minsk – 1,11, the lowest incidence rate was determined in the Vitebsk region – 0,68 per 100,000 population per year, p<0,05. The maximum incidence rates of essential thrombocythemia were recorded in Minsk city – 1,04 and Gomel region – 0,86, which is significantly higher than in Minsk region – 0,27, Vitebsk region – 0,35 and Grodno region – 0,44 per 100 000 population per year. The highest incidence rates of primary myelofibrosis were noted in Gomel – 0,63 and Vitebsk regions – 0,53, they were significantly higher than in Grodno – 0,14 and Minsk regions – 0,24 per 100 000 population per year.

Differences in the incidence of Ph-MPN between the regions of Belarus were revealed, while the overall incidence rates in Minsk city, Gomel, Brest and Mogilev regions exceeded those in Vitebsk, Grodno and Minsk regions. In addition, variation in incidence rates for individual nosologies was noted. The information obtained can be used to make management decisions when organizing medical observation and treatment of patients with Ph- MPN in Belarus.

1. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms R.M. Shallis [et al.] // Hematol. Oncol. Clin. North Am. – 2021. – Vol. 35, №2. – P. 177-189.

2. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map / R.M. Shallis [et al.] // Blood Rev. – 2020. – Vol. 42. – P. 100706.

3. Диагностика и лечение Ph-негативных миелопролиферативных новообразований в военно- медицинских организациях Министерства обороны Российской Федераци : методические рекоменда-ции / А.С. Поляков [et al.]. – С.-Пб.: Военно-медицинская академия имени С.М. Кирова, 2020. – 84 с.

4. How common are myeloproliferative neoplasms? A systematic review and meta-analysis / G.J. Titmarsh [et al.] // Am. J. Hematol. – 2014. – Vol. 89, № 6. – P. 581-587.

5. Абдулкадыров, К.М. Миелопролифератив- ные новообразования / К.М. Абдулкадыров, В. Шува- ев, И.С. Мартынкевич. – М.: Литтерра, 2016. – 304 с.

6. Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study / M. Hultcrantz [et al.] // J. Clin. Oncol. – 2012. – Vol. 30, №24. – P. 2995-3001.

7. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway / C. Roaldsnes [et al.] // Eur. J. Haematol. – 2017. – Vol. 98, №1. – P. 85-93.

8. Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population-based study in Sweden / M. Hultcrantz [et al.] // J. Intern. Med. – 2020. – Vol. 287, №4. – P. 448-454.

9. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion / T. Barbui [et al.] // Blood Cancer J. – 2018. – Vol. 8, №2. – P. 15.

10. Tefferi, A. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms / A. Tefferi, J. W. Vardiman // Leukemia. – 2008. – Vol. 22, №1. – P. 14-22.

11. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia / D.A. Arber [et al.] // Blood. – 2016. – Vol. 127, №20. – P. 2391-2405.

12. Segi, M. Cancer mortality for selected sites in 24 Countries (1950-1957) / M. Segi. – Sendai : Department of Public Health, Tohoku University School of Medicine, 1960.

13. QGIS Geographic Information System v. 3.8.2 [Electronic resource] / QGIS Development Team. 2022. – Mode of access: https://www.qgis.org. – Date of access: 15.08.2022.